Biotech body criticises Bayer on cancer drug

The All India Biotech Association – Southern Chapter (AIBA-SC) has come out strongly in favour of the Indian Patents Office order in favour of Natco Pharma Ltd.
The association has criticised Bayer for not agreeing to the “fair decision”.
http://www.thehindubusinessline.com/companies/article3412659.ece?ref=wl_opinion

Biocon-Mylan collaboration drug portfolio worth $33 bn

Biocon in an investor presentation has revealed that it is sitting on a potential $33 billion portfolio of biosimilar drugs that will expire by 2015

The two companies are planning to come out with biosimilars such as "Trastuzumab, Peg-filgrastim, Bevacizumab, Adalimumab and Eternacept", which could be used in treating various ailments including cancer and psoriasis.
http://www.business-standard.com/india/news/biocon-mylan-collaboration-drug-portfolio-worth-33-bn/164500/on

Bayer challenges Nexavar generic licence order

In March this year, India had invoked a law permitting Hyderabad-based Natco Pharma to manufacture and sell cancer-treatment drug Nexavar at a price over 30 times lower than charged by its patent-holder Bayer Corporation
In his order, Controller of Patents PH Kurian had said the move followed Bayer not doing enough to scale up the sale of the drug despite getting patent for it in India in 2008
http://articles.economictimes.indiatimes.com/2012-05-07/news/31610564_1_drugmaker-bayer-indian-patent-act-cancer-drug